Immunsystem AB   Report issue

For profit Phase 2
Founded: Stockholm Sweden (1983)
Status: No NME R&D (1983)

Organization Overview

First Clinical Trial
2003
NCT00633191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2003

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

pseudigy (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Infections (Phase 2)

Pseudomonas Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1